Literature DB >> 18023487

A new dose-volume-based Plan Quality Index for IMRT plan comparison.

Lucullus Hing Tong Leung1, Monica Wai Kwan Kan, Ashley Chi Kin Cheng, Wicger King Hang Wong, Chun Chung Yau.   

Abstract

BACKGROUND AND PURPOSES: To develop a dose-volume-based Plan Quality Index for IMRT plans.
MATERIALS AND METHODS: This study used a H(ealthy) Tissue Conformity Index to describe the overall plan conformity, a M(erit) function to describe the target coverage and a P(enalty) function to evaluate doses to critical organs. The Euclidean distance (PQI) between (H, M, P) and (1,1,1) represented the quality of a treatment plan. By checking the polarity of each term in M and P, one might conclude if the plan was satisfied with the given treatment protocol. Ten prostate plans (3-DCRT and IMRT) and 20 NPC IMRT plans were used to test PQI, Conformation Number (CN), COnformal INdex (COIN). EUD was used as a vehicle to explain the results. This study defined the power of a quality index as the ratio of the absolute difference to the mean of the same index of two plans, to compare the discerning power of PQI, CN and COIN.
RESULTS: The plan quality discerning power of PQI, COIN and CN was 20.6%, 8.2% and 5.5%, respectively, in prostate plans.
CONCLUSION: PQI improved the plan quality discerning power and was capable of discerning qualified and unqualified treatment plans.

Mesh:

Year:  2007        PMID: 18023487     DOI: 10.1016/j.radonc.2007.10.018

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  16 in total

1.  Reduced order constrained optimization (ROCO): clinical application to lung IMRT.

Authors:  Hans Stabenau; Linda Rivera; Ellen Yorke; Jie Yang; Renzhi Lu; Richard J Radke; Andrew Jackson
Journal:  Med Phys       Date:  2011-05       Impact factor: 4.071

2.  SPIDERplan: A tool to support decision-making in radiation therapy treatment plan assessment.

Authors:  Tiago Ventura; Maria do Carmo Lopes; Brigida Costa Ferreira; Leila Khouri
Journal:  Rep Pract Oncol Radiother       Date:  2016-08-24

3.  New conformity indices based on the calculation of distances between the target volume and the volume of reference isodose.

Authors:  J M Park; S-Y Park; S-J Ye; J H Kim; J Carlson; H-G Wu
Journal:  Br J Radiol       Date:  2014-09-16       Impact factor: 3.039

4.  Modeling physician's preference in treatment plan approval of stereotactic body radiation therapy of prostate cancer.

Authors:  Yin Gao; Chenyang Shen; Yesenia Gonzalez; Xun Jia
Journal:  Phys Med Biol       Date:  2022-05-26       Impact factor: 4.174

5.  A computational tool for the efficient analysis of dose-volume histograms from radiation therapy treatment plans.

Authors:  Anil Pyakuryal; W Kenji Myint; Mahesh Gopalakrishnan; Sunyoung Jang; Jerilyn A Logemann; Bharat B Mittal
Journal:  J Appl Clin Med Phys       Date:  2010-01-28       Impact factor: 2.102

6.  Helical tomotherapy for single and multiple liver tumours.

Authors:  Tsair-Fwu Lee; Pei-Ju Chao; Fu-Min Fang; Te-Jen Su; Stephen W Leung; Hsuan-Chih Hsu
Journal:  Radiat Oncol       Date:  2010-06-24       Impact factor: 3.481

7.  Use of a correlation analysis model in the optimization of intensity-modulated radiotherapy of prostate cancer.

Authors:  Xiadong Li; Qinghua Deng; Shenglin Ma; K E Zhang; Zhibing Wu; Jianjun Lai; Rongjun Tang; Yao Ren; Jiahao Wang; Lixia Xu
Journal:  Exp Ther Med       Date:  2015-10-26       Impact factor: 2.447

Review 8.  Plan evaluation indices: A journey of evolution.

Authors:  Ganeshkumar Patel; Abhijit Mandal; Sunil Choudhary; Ritusha Mishra; Ravindra Shende
Journal:  Rep Pract Oncol Radiother       Date:  2020-03-04

9.  A dose-volume histogram based decision-support system for dosimetric comparison of radiotherapy treatment plans.

Authors:  J C L Alfonso; M A Herrero; L Núñez
Journal:  Radiat Oncol       Date:  2015-12-29       Impact factor: 3.481

10.  Dose gradient curve: A new tool for evaluating dose gradient.

Authors:  KiHoon Sung; Young Eun Choi
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.